Objective-To evaluate the influence of antihypertensive treatment and metabolic characteristics on the development of diabetes mellitus in middle aged men.
Subjects and methods The hypertensive and control groups were derived from a larger cohort ofmen who were participating in a health survey and who were examined in and again in 1980-3.
HYPERTENSIVE GROUP
The initial health survey was conducted among 2322 men born in 1920-4 and who therefore were aged 50 at the time of first examination.'2 Of the 174 men identified who had primary hypertension (figure), 87 were newly diagnosed cases (untreated diastolic pressure -105 mm Hg on two occasions) and 87 already receiving treatment. Treatment at a special hypertension clinic was offered to all these men, 91 of whom declined because they were attending other physicians. The remaining 83 men accepted and subsequently were checked twice a year for almost a decade.'3 Three of the hypertensive men were known to be diabetic at the time of the first health survey and had blood glucose concentrations of 6 7-9-8 mmol/l.
All men in the first health survey who had serum cholesterol or triglyceride concentrations, or both, above the 80th centile on two occasions were treated for hyperlipidaemia. Twenty three of the hypertensive men were given dietary advice for this reason. Pharmacological treatment of hypertension, however, was given priority over pharmacological treatment of hyperlipidaemia in the hyperlipidaemic hypertensives. Flow The intravenous glucose tolerance test was performed by the same method in the two surveys. At the first screening examination 1692 of the 2322 participants were tested. Glucose 0 5 g/kg as a 50% solution was given into an antecubital vein over about two and a half minutes. Samples for blood glucose determination were drawn before and 20, 30, 40, 50, and 60 minutes after the start of the injection. The subjects remained supine throughout. Glucose tolerance was expressed as the k value, as described. '6 In addition, the fasting blood glucose concentration was measured in all subjects and an oral glucose tolerance test performed at follow up in those with values higher than 5 6 mmol/l. A dose of 75 g glucose in 300 ml water was given and blood samples for glucose assay taken before and 30, 60, 90, and 120 minutes after intake. On the basis of the oral glucose tolerance test the subjects were divided into those with normal or impaired glucose tolerance and those with diabetes mellitus, as defined by the National Diabetes Data Group. '7 In contrast with the recommendation of that group, however, only one oral glucose tolerance test was performed. The classification of diabetes at the first investigation was made in retrospect and thus was based on a fasting blood glucose concentration (available in all subjects) of -6-7 mmol/l either alone or in combination with a k value of -0 9 from the intravenous glucose tolerance test, which was performed in 54 ofthe 73 The cholesterol concentration in high density lipoprotein was assayed in the supernatant after precipitation of the very low and low density lipoproteins with heparin manganese chloride. '9 QUESTIONNAIRE A self administered medical questionnaire20 was used in the initial health survey to obtain familial and personal medical histories, including data on heritable factors, smoking, and physical activity. The same questions were asked in the follow up survey.
STATISTICAL ANALYSIS
An interaction test2' was applied for comparisons of changes between groups and between time points within groups. The model included factors for patient, group, time points, and group-time interaction. In one analysis diabetic state was used as an additional factor.
Results
The average length of the observation period was 9 3 (range 7-11) years for both groups (SD 0 73 for hypertensive men, 0-89 for controls). After nearly 10 years of treatment 79 men were still visiting the hypertension clinic. One died shortly before the reexamination date, one could not attend because of illness, and four failed to attend. Thus 73 hypertensive men were re-examined. Of 78 controls re-examined, 13 were taking thiazides or other blood pressure lowering drugs. Those receiving treatment were excluded from the analysis (none had diabetes); the final control group therefore comprised 65 men, none of whom had had diabetes when seen in 1970-3.
Five controls and two hypertensive men were receiv- ing lipid lowering agents at re-examination. These men, along with those who had been given dietary advice during the follow up period (16 hypertensive men only), were also excluded from the final analysis when comparisons were made of metabolic changes over time; dietary treatment and hypolipidaemic drugs may affect serum lipid, glucose, and insulin values. Treatment of hypertension-Propranolol was given as the first drug in previously untreated subjects. The next step, if required, was to add hydralazine, followed by thiazides ifblood pressure was still not satisfactorily controlled. Propranolol was later changed to atenolol Tables I and II give (table V) , whereas in the control group it had increased by 14/8 mm Hg. Body weight had increased by 2 0 kg in the hypertensive group and 1-3 kg in the controls. The k value remained unaltered in the control group but had decreased in the hypertensive group from 1V71 to 1-28 (-34%; p=0-015). This change, however, was not significantly different from the change in the controls (table V) . These comparisons were made after excluding all men who had developed diabetes or who were receiving treatment (table VII) . The fasting serum insulin concentration increased in non-diabetic hypertensives compared with non-diabetic controls (table VI) , but not significantly. There was no change with time in peak serum insulin concentration in non-diabetic hypertensives relative to controls, though the value in diabetic hypertensives showed a substantial fall (p<O-000l) (table VI). The insulin index (table VII) decreased with time in both non-diabetic and diabetic hypertensives compared with non-diabetic controls.
Discussion
The incidence of diabetes mellitus among people with untreated hypertension is not known. In this study, however, the hypertensive men who later developed diabetes differed from those who did not with respect to metabolic variables and showed signs of disturbed glucose metabolism at around the age of 50, many years before the onset of diabetes. Thus they had a higher fasting serum insulin concentration and lower peak serum insulin concentration (p=0 064), giving a lower insulin index at the initial examination. They also had a higher body mass index and serum triglyceride concentration and a lower (p=04065), but still normal, k value compared with those hypertensive men who did not develop diabetes. Several of these signs-for example, a high fasting serum insulin BMJ VOLUME 298 
Abstract
Objective-To compare the effects of metoprolol and atenolol on carbohydrate and lipid metabolism and on insulin response to an intravenous glucose load.
Design-Randomised, double blind, double dummy, controlled crossover trial.
Setting-University Hospital, Uppsala, Sweden. Patients-60 Patients with primary hypertension (diastolic blood pressure when resting supine 95-119 mm Hg on at least two occasions during four to six weeks of treatment with placebo) randomised to receive either metoprolol (n=30) or atenolol (n=30) during the first treatment period.
Interventions-Placebo was given for a run in period of four to six weeks. Metoprolol 100 mg twice daily or atenolol 25 mg twice daily was then given for 16 weeks. The two drugs were then exchanged and treatment continued for a further 16 weeks.
End point-Evaluation of effects of treatment with metoprolol and atenolol on glucose, insulin, and lipid metabolism and glucose disposal mediated by insulin.
Measurements and main results-Reduction of blood pressure *as similar and satisfactory during treatment with both drugs. Glucose uptake mediated by insulin was measured during a euglycaemic hyperinsulinaemic clamp to evaluate patients' sensitivity to insulin. Glucose uptake decreased from 5-6 to 4-5 mglkg/min when patients were taking metoprolol and from 56 to 4-9 mg/kg/min when they were taking atenolol. Both. drugs caused a small increase in fasting plasma ipsulin and blood glucose concentrations and glycated haemoglobin concentration. Despite decreased sensitivity to insulin the increase in insuli concentration in response to an intravenous glucose tolerance test was small, suggesting inhibition of release of insulin. Very low density lipoprotein and low density lipoprotein triglyceride concentrations were increased with both drugs and high density lipoprotein cholesterol concentration was decreased. Low density lipoprotein cholesterol concentration was not affected.
Conclusions-Long term use of metoprolol and atenolol causes metabolic abnormalities that may be related to the increased incidence of diabetes in patients with hypertension who are treated pharmacologicaily. These results may help to explain why the two drugs have failed consistently to reduce the incidence of coronary heart disease in several large scale studies.
Introduction
During the past 20 years there has been much emphasis on detecting and treating hypertension, which is an important risk factor for cardiovascular disease,' and several large scale trials have shown that a reduction in blood pressure is associated with a decrease in cardiovascular morbidity and mortality. [2] [3] [4] [5] Some ofthe drugs used to treat hypertension, however, have adverse effects, including disturbances of serum lipid concentrations and glucose metabolism.5"7 Treatment with thiazide diuretics and f3 blockers has been associated with an increased incidence of impaired glucose tolerance6 and diabetes.57 Few attempts have been made, however, to evaluate specific influences of pharmacological treatment of hypertension on glucose metabolism-for example, to determine whether it decreases secretion of insulin or sensitivity to insulin, or both. Sensitivity%to insulin may be important as studies have shown that hypertension is accompanied by resistance to instin.8J10
We evaluated the effect of long term treatment with two widely used P I 3 adrenergic blockers, metoprolol and atenolol, on glucose disposal mediated by insulin and examined their effects on glucose, insulin, and lipid metabolism.
Patients and methods

CRITERIA FOR INCLUSION
Patients were recruited from a health screening survey in Uppsala, Sweden. All had primary hypertension, defined as a stable diastolic blood pressure when resting supine of 95-119 mm Hg on at least two occasions during four to six weeks of treatment with placebo. Any current antihypertensive treatment was stopped and a placebo was given single blind for four to six weeks. Patients with newly detected hypertension were followed up for three to four months to make sure that their raised blood pressure was stable before they entered the single blind placebo period.
CRITERIA FOR EXCLUSION
Criteria for exclusion were: clinical or laboratory evidence of hepatic or renal disease, obstructive pulmonary disease, Raynaud's disease, or thyroid dys-
